BIOSECURE Act Diluted Significantly, But China Plus Strategy Still Accelerating: Strides MD
Significant growth expected in H2 FY25
A time extension to US companies to shift business away from a few Chinese firms under the proposed BIOSECURE Act has disappointed the Strides MD. However, the China plus strategy continues to drive business and capacity expansion for auto-injectors required by GLP-1 customers is expected
